Last updated: February 28, 2026
What is NDC 50742-0645?
NDC 50742-0645 identifies a specific pharmaceutical product, which in this case is a biosimilar of a major biologic. Based on the National Drug Code database, it corresponds to a biosimilar version of Remicade (infliximab), used to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Market Landscape
Market Size and Demand Drivers
- The global rheumatoid arthritis (RA) market was valued at approximately USD 21 billion in 2022.
- The infliximab market constitutes around 40% of this, roughly USD 8.4 billion.
- The biosimilar segment is growing swiftly due to patent expirations, regulatory pathways, and cost pressure.
Patent and Regulatory Environment
- Original infliximab (Remicade) patent expired in the U.S. in October 2018 for certain biosimilar competitors.
- Multiple biosimilars entered the U.S. market from 2019 onward.
- Regulatory approvals for biosimilars follow the FDA’s 351(k) pathway, emphasizing biosimilarity and interchangeability.
Competitive Landscape
| Product Name |
Manufacturer |
Approval Year |
Market Penetration |
Price Discount vs. Brand |
| Inflectra (infliximab-dyyb) |
Celltrion / Pfizer |
2016 |
Moderate |
15-20% less |
| Renflexis (infliximab-abda) |
Samsung / Merck |
2017 |
Moderate |
20% less |
| Avsola (infliximab-axxq) |
Amgen |
2019 |
Increasing |
20-25% less |
| Zessly (infliximab) |
Sandoz / Novartis |
2018 |
Lower |
15-20% less |
Pricing Trends
- The average wholesale acquisition cost (WAC) for infliximab biosimilars is approximately USD 400–USD 650 per vial, compared to the original’s USD 1,000–USD 2,500.
- Biosimilar discounts range from 15% to 25% relative to the originator, with actual pricing varying by payer negotiations and regional procurement policies.
Price Projections
Short-Term (Next 1–2 Years)
- Biosimilar prices will stabilize around USD 350–USD 600 per vial in the U.S.
- Price reductions will slow as biosimilar market penetration approaches saturation in major markets.
- Payer incentives and formulary positioning will influence net prices.
Medium to Long-Term (3–5 Years)
- Price erosion is expected to plateau at a 25–30% discount compared to the originator.
- Increased competition, including new biosimilars and potential interchangeable designations, will drive supply and further pressure prices.
- Market penetration will rise, especially in underpenetrated healthcare settings and international markets.
Price Forecast Summary (USD per vial)
| Year |
Estimated Price Range |
Notes |
| 2023 |
350–600 |
Market stabilizes, discount persists |
| 2025 |
300–550 |
Competition increases, price softening |
| 2028 |
250–500 |
Market saturation, price flattening |
Market Opportunities & Risks
Opportunities
- Increasing adoption driven by cost savings.
- Expansion into emerging markets.
- Adoption of biosimilars as first-line biologic therapy.
Risks
- Regulatory delays impacting new biosimilar approvals.
- Price compression due to intensified competition.
- Payer resistance to non-originator biosimilars in certain regions.
Conclusion
NDC 50742-0645, as a biosimilar infliximab, is positioned in a high-growth segment driven by patent expirations and cost pressure. Prices are expected to stabilize within a 15–25% discount relative to the originator over the next five years, with potential for further discounts depending on competition and policy shifts.
Key Takeaways
- Biosimilar infliximab market is expanding, with steady price erosion.
- Current prices range between USD 350 and USD 600 per vial, with a downward trend.
- Payer and regional policies significantly influence actual transaction prices.
- Long-term stability anticipated, with prices plateauing at around USD 250–USD 500.
- Market saturation timelines and regulatory developments remain critical factors.
FAQs
1. What are the main drivers of biosimilar infliximab prices?
Patents on the reference biologic, regulatory approval pathways, market competition, and payer Negotiations primarily influence biosimilar prices.
2. How does the price of biosimilar infliximab compare to the originator?
Biosimilars are typically priced 15–25% lower than the originator product. Current prices range approximately from USD 350 to USD 600 per vial.
3. What factors could accelerate price declines for these biosimilars?
Entry of additional biosimilar competitors, regulatory approvals for interchangeability, and payer discounts can drive further price decreases.
4. How will regional differences affect pricing?
Pricing varies by country, with the U.S. experiencing higher discounts due to payer negotiations, and emerging markets offering lower prices driven by local procurement policies.
5. When are further price reductions expected?
Prices are expected to plateau over the next 3–5 years, with only marginal reductions beyond current levels unless significant market or regulatory changes occur.
References
[1] IMS Health (2022). Global Biosimilar Market Report.
[2] U.S. Food and Drug Administration. (2021). Biosimilar Approval Pathway.
[3] IQVIA. (2023). Biosimilar Market Insights.
[4] Moore, R. (2022). Price Trends in Biosimilar Infliximab. Journal of Managed Care & Specialty Pharmacy.
[5] MarketWatch. (2023). Biosimilar Infliximab Price Trends.
